JP2019534044A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019534044A5 JP2019534044A5 JP2019545717A JP2019545717A JP2019534044A5 JP 2019534044 A5 JP2019534044 A5 JP 2019534044A5 JP 2019545717 A JP2019545717 A JP 2019545717A JP 2019545717 A JP2019545717 A JP 2019545717A JP 2019534044 A5 JP2019534044 A5 JP 2019534044A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nos
- amino acid
- antibody
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022087695A JP7455897B2 (ja) | 2016-11-08 | 2022-05-30 | 抗ｐｄ１および抗ｃｔｌａ４抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662419157P | 2016-11-08 | 2016-11-08 | |
| US62/419,157 | 2016-11-08 | ||
| PCT/US2017/060122 WO2018089293A2 (en) | 2016-11-08 | 2017-11-06 | Anti-pd1 and anti-ctla4 antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022087695A Division JP7455897B2 (ja) | 2016-11-08 | 2022-05-30 | 抗ｐｄ１および抗ｃｔｌａ４抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019534044A JP2019534044A (ja) | 2019-11-28 |
| JP2019534044A5 true JP2019534044A5 (https=) | 2021-02-12 |
Family
ID=60409406
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019545717A Pending JP2019534044A (ja) | 2016-11-08 | 2017-11-06 | 抗ｐｄ１および抗ｃｔｌａ４抗体 |
| JP2022087695A Active JP7455897B2 (ja) | 2016-11-08 | 2022-05-30 | 抗ｐｄ１および抗ｃｔｌａ４抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022087695A Active JP7455897B2 (ja) | 2016-11-08 | 2022-05-30 | 抗ｐｄ１および抗ｃｔｌａ４抗体 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11124570B2 (https=) |
| EP (1) | EP3538137A2 (https=) |
| JP (2) | JP2019534044A (https=) |
| CN (2) | CN118480125A (https=) |
| AU (1) | AU2017356860A1 (https=) |
| CA (1) | CA3042249A1 (https=) |
| WO (1) | WO2018089293A2 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017269115B2 (en) * | 2016-05-26 | 2024-06-20 | Qilu Puget Sound Biotherapeutics Corporation | Mixtures of antibodies |
| CA3042249A1 (en) | 2016-11-08 | 2018-05-17 | Qilu Puget Sound Biotherapeutics Corporation | Anti-pd1 and anti-ctla4 antibodies |
| JP7625521B2 (ja) * | 2018-12-28 | 2025-02-03 | トランスジーン | ｍ２欠陥ポックスウイルス |
| US20220235144A1 (en) | 2019-03-04 | 2022-07-28 | Qilu Puget Sound Biotherapeutics Corporation | Anti-sirp-alpha antibodies |
| EP4021579A1 (en) | 2019-08-30 | 2022-07-06 | Qilu Puget Sound Biotherapeutics Corporation | Anti-cd20 antibodies, anti-cd37 antibodies, and mixtures thereof |
| US12473349B2 (en) * | 2020-05-06 | 2025-11-18 | Korea University Research And Business Foundation | PD-1 variants having increased PD-L1 affinity |
| CN111875697B (zh) * | 2020-08-03 | 2021-10-01 | 杭州皓阳生物技术有限公司 | 一种包含肽标签的融合蛋白 |
| EP4294531A4 (en) * | 2021-02-18 | 2025-07-16 | Qilu Puget Sound Biotherapeutics Corp | COMBINATIONS OF ANTI-PD1 AND ANTI-CTLA4 ANTIBODIES |
| WO2023160517A1 (zh) * | 2022-02-22 | 2023-08-31 | 齐鲁制药有限公司 | 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途 |
| CN119255817A (zh) * | 2022-03-28 | 2025-01-03 | 齐鲁制药有限公司 | 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途 |
| CN118946366A (zh) * | 2022-04-13 | 2024-11-12 | 齐鲁制药有限公司 | 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途 |
| US20250313643A1 (en) * | 2022-06-07 | 2025-10-09 | Unm Rainforest Innovations | Humanized non-opioid composition and therapies for pain management |
| WO2024002074A1 (zh) * | 2022-06-28 | 2024-01-04 | 齐鲁制药有限公司 | 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途 |
| WO2024002226A1 (zh) * | 2022-06-30 | 2024-01-04 | 齐鲁制药有限公司 | 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途 |
| TW202525861A (zh) * | 2023-12-01 | 2025-07-01 | 大陸商齊魯製藥有限公司 | 穩定的混合抗體的藥物組合物 |
| WO2025228542A1 (en) | 2024-05-03 | 2025-11-06 | Genmab B.V. | Method for co-expression of a plurality of antibodies |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU670075B2 (en) | 1992-02-26 | 1996-07-04 | Allergan, Inc. | Use of platelet derived growth factor in ophthalmic wound healing |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| DK1141028T3 (da) * | 1998-12-23 | 2010-05-25 | Pfizer | Humane monoklonale antistoffer til CTLA-4 |
| US6682736B1 (en) * | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| IL148079A0 (en) * | 1999-08-24 | 2002-09-12 | Medarex Inc | Human ctla-4 antibodies and compositions containing the same |
| RU2494107C2 (ru) * | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| GB0514779D0 (en) | 2005-07-19 | 2005-08-24 | Celltech R&D Ltd | Biological products |
| CA2647282A1 (en) | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| ES2563027T3 (es) | 2008-01-07 | 2016-03-10 | Amgen Inc. | Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática |
| WO2009100140A1 (en) | 2008-02-04 | 2009-08-13 | Medarex, Inc. | Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof |
| EP2286220A2 (en) * | 2008-05-29 | 2011-02-23 | Bristol-Myers Squibb Company | Methods for predicting patient response to modulation of the co-stimulatory pathway |
| JO3246B1 (ar) | 2009-09-09 | 2018-03-08 | Regeneron Pharma | اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري |
| CA2777226A1 (en) * | 2009-10-12 | 2011-04-21 | Pfizer Inc. | Cancer treatment |
| EP2630160B1 (en) | 2010-10-18 | 2016-11-09 | MediaPharma S.r.l. | Erbb3 binding antibody |
| IN2013MN01438A (https=) | 2011-03-17 | 2015-06-12 | Univ Ramot | |
| CN202105787U (zh) | 2011-06-03 | 2012-01-11 | 杨自强 | 糠粞分离机 |
| JP6238459B2 (ja) | 2011-08-01 | 2017-11-29 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法 |
| CN102851338A (zh) | 2012-07-25 | 2013-01-02 | 苏州康宁杰瑞生物科技有限公司 | 利用电荷排斥作用制备同二聚体蛋白混合物的方法 |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| US10118971B2 (en) | 2013-03-13 | 2018-11-06 | Ibentrus, Inc. | Protein in which electrical interaction is introduced within hydrophobic interaction site and preparation method therefor |
| MY184154A (en) * | 2013-12-12 | 2021-03-23 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| TWI681969B (zh) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| US10954301B2 (en) * | 2015-12-14 | 2021-03-23 | Macrogenics, Inc. | Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof |
| CA3042249A1 (en) | 2016-11-08 | 2018-05-17 | Qilu Puget Sound Biotherapeutics Corporation | Anti-pd1 and anti-ctla4 antibodies |
-
2017
- 2017-11-06 CA CA3042249A patent/CA3042249A1/en active Pending
- 2017-11-06 AU AU2017356860A patent/AU2017356860A1/en not_active Abandoned
- 2017-11-06 CN CN202410423333.9A patent/CN118480125A/zh active Pending
- 2017-11-06 US US16/347,554 patent/US11124570B2/en active Active
- 2017-11-06 JP JP2019545717A patent/JP2019534044A/ja active Pending
- 2017-11-06 EP EP17801203.5A patent/EP3538137A2/en active Pending
- 2017-11-06 WO PCT/US2017/060122 patent/WO2018089293A2/en not_active Ceased
- 2017-11-06 CN CN201780069181.5A patent/CN110312523B/zh active Active
-
2021
- 2021-09-16 US US17/477,525 patent/US12037397B2/en active Active
-
2022
- 2022-05-30 JP JP2022087695A patent/JP7455897B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019534044A5 (https=) | ||
| ES2777603T3 (es) | Anticuerpos PD-L1 ("ligando de muerte programada 1") | |
| JP2020516240A5 (https=) | ||
| JP2018527919A5 (https=) | ||
| RU2018134065A (ru) | Антитела, специфические к рецептору полиовируса (pvr) человека | |
| JP2017532952A5 (https=) | ||
| KR102104296B1 (ko) | 종양성 질병들에 대한 치료 | |
| JP2025065211A (ja) | 癌の治療における有効性の増強のためのｐｄ－１阻害剤とｌａｇ－３阻害剤の組み合わせ | |
| FI3459597T3 (fi) | Yksiketjuinen vasta-aine ctla4:lle ja siitä johdettu proteiini | |
| JP2017535257A5 (https=) | ||
| RU2019104980A (ru) | Анти-icos антитела | |
| CN102753195A (zh) | 用于增强抗肿瘤抗体疗法的方法 | |
| JP2019528683A5 (https=) | ||
| JP2018532383A5 (https=) | ||
| AU2020363041B2 (en) | Antibodies against the poliovirus receptor (PVR) and uses thereof | |
| AU2020207664A1 (en) | Antibodies specific to human Nectin-2 | |
| CN113412124A (zh) | Baff-r双特异性t细胞衔接子抗体 | |
| JPWO2019165340A5 (https=) | ||
| CA3062479A1 (en) | Bispecific recombinant protein and use thereof | |
| CN113501879B (zh) | 一种解除肿瘤免疫微环境中免疫抑制的双功能抗体及其应用和制备方法 | |
| IL277899B1 (en) | Methods and compositions for treating yellow fever | |
| JPWO2020144697A5 (https=) | ||
| JP2026506070A (ja) | 抗ｃｎｔｎ４抗体及びその使用 | |
| CN106963950B (zh) | 用于治疗肿瘤的联合用药物 | |
| AU2015271978B2 (en) | Treatment for neoplastic diseases |